Literature DB >> 8625556

Expression and function of monocyte chemoattractant protein-1 in experimental nephrotic syndrome.

A A Eddy1, J S Warren.   

Abstract

This study investigates the expression and function of monocyte chemoattractant protein-1 (MCP-1) in rats with aminonucleoside nephrosis induced by a single intraperitoneal injection of puromycin aminonucleoside (PAN). On Day 7, PAN-treated rats had a sixfold increase in renal MCP-1 messenger (m)RNA levels and a twofold increase in interleukin-1 beta mRNA levels. During the course of PAN nephrosis, most of the de novo MCP-1 protein resembled protein droplets that were prominent in glomeruli between Days 3 and 14 and weaker but visible in tubules between Days 5 and 10. In addition, occasional tubules showed a cytoplasmic staining pattern for MCP-1. Two studies evaluated the effect of MCP-1 neutralization on renal monocyte recruitment. In the first study, PAN-treated rats were treated with affinity-purified MCP-1-neutralizing rabbit IgG on Days 0, 1, 3, and 5; kidneys were harvested on Day 7. There was no difference in the mean number of interstitial macrophages [119 +/- 28 vs 88 +/- 9 ED-1+ cells/1000 tubulointerstitial (TI) cells; 106 +/- 28 vs 119 +/- 33 Ia+ cells/1000 TI cells] or intraglomerular macrophages [2.0 +/- 0.9 vs 1.7 +/- 0.5 ED-1+ cells/glomerular cross section (gcs); 1.2 +/- 0.3 vs 1.1 +/- 0.4 Ia+ cells/gcs] compared with nephrotic rats treated with nonimmune rabbit IgG. In the second study, a group of PAN-treated rats was treated with MCP-1-neutralizing IgG administered continuously by an intraperitoneal miniosmotic pump for 7 days and was compared with a control group treated in an identical fashion with PAN and nonimmune IgG. On Day 7 there was no difference in the mean number of interstitial macrophages (55 +/- 45 vs 67 +/- 16 ED-1+ and 70 +/- 63 vs 61 +/- 13 Ia+ cells/1000 TI cells) and intraglomerular macrophages (1.0 +/- 0.4 vs 1.6 +/- 0.9 ED-1+ and 0.6 +/- 0.1 vs 1.1 +/- 0.7 Ia+ cells/gcs). The results of this study suggest that although MCP-1 gene and protein expression are increased in the kidneys of rats with aminonucleoside nephrosis, MCP-1 does not appear to play an essential role in early renal monocyte recruitment in this model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625556     DOI: 10.1006/clin.1996.0023

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  5 in total

1.  Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis.

Authors:  A Nomura; Y Morita; S Maruyama; N Hotta; M Nadai; L Wang; T Hasegawa; S Matsuo
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Cytokines in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases.

Authors:  Heloisa Reniers Vianna; Cristina Maria Bouissou M Soares; Katia Daniela Silveira; Gustavo Siqueira Elmiro; Philipe Melgaço Mendes; Marcelo de Sousa Tavares; Mauro Martins Teixeira; Débora Marques Miranda; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2012-11-18       Impact factor: 3.714

3.  The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes.

Authors:  Davina Burt; Gennaro Salvidio; Elena Tarabra; Federica Barutta; Silvia Pinach; Patrizia Dentelli; Giovanni Camussi; Paolo Cavallo Perin; Gabriella Gruden
Journal:  Am J Pathol       Date:  2007-11-30       Impact factor: 4.307

4.  RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis.

Authors:  C M Lloyd; A W Minto; M E Dorf; A Proudfoot; T N Wells; D J Salant; J C Gutierrez-Ramos
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

Review 5.  Chemokines as potential markers in pediatric renal diseases.

Authors:  Ana Cristina Simões e Silva; André Barreto Pereira; Mauro Martins Teixeira; Antônio Lúcio Teixeira
Journal:  Dis Markers       Date:  2014-02-17       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.